Cellectis received proceeds of €13 Million through the exercise of warrants

Published on November 12, 2014

Back to all press releases

November 12, 2014 – Paris (France) – Cellectis (Alternext: ALCLS.PA), a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CART cells (UCART), announces that it has received €13,237,524 ($16.5M) through the exercise of 7,354,180 warrants of the 12,195,113 warrants issued in October 2011, which expired on October 28, 2014 (60.3% of the total amount).

An additional 1,470,836 new shares were issued as a result of such exercise.

“We would like to thank our shareholders for their continued support”, said Dr. André Choulika, Chairman & CEO of Cellectis. “These additional funds, along with the Company’s existing cash and cash equivalents, provide Cellectis with a strong balance sheet that will allow us to continue to execute our strategy focused on developing our therapeutic programs and to advance our product development activities at Cellectis plant sciences.”

Download the PDF file